CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Yervoy for advanced melanoma - Details

Project Number PC0003-000
Brand Name Yervoy
Generic Name Ipilimumab
Strength 5 mg/mL
Tumour Type Skin and Melanoma
Indication Advanced Melanoma
Funding Request Treatment of advanced melanoma (unresectable Stage III and IV melanoma) in patients who have received prior systemic therapy
Review Status Complete
Pre Noc Submission Yes
NOC Date February 1, 2012
Manufacturer Bristol-Myers Squibb Canada
Sponsor Bristol-Myers Squibb Canada
Submission Date December 1, 2011
Submission Deemed Complete December 7, 2011
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ December 15, 2011
Check-point meeting January 24, 2012
pERC Meeting March 15, 2012
Initial Recommendation Issued March 29, 2012
Feedback Deadline ‡ April 16, 2012
Final Recommendation Issued April 18, 2012
Notification to Implement Issued May 2, 2012
Therapeutic Area Advanced Melanoma
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.